Keyur P. Patel

Active 2010–2025

167
Papers
20,110
Citations
76
h-index
163
i10-index

Citations

Citations per year for Keyur P. Patel2001: 2 citations2009: 1 citations2010: 2 citations2011: 4 citations2012: 10 citations2013: 15 citations2014: 31 citations2015: 81 citations2016: 119 citations2017: 168 citations2018: 142 citations2019: 610 citations2020: 791 citations2021: 907 citations2022: 877 citations2023: 924 citations2024: 1,481 citations2025: 704 citations2026: 6 citations2002–2008: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,768 citing papers, 31.2% of this breakdownChina: 633 citing papers, 7.1% of this breakdownItaly: 611 citing papers, 6.9% of this breakdownGermany: 540 citing papers, 6.1% of this breakdownUnited Kingdom: 490 citing papers, 5.5% of this breakdownFrance: 434 citing papers, 4.9% of this breakdownSpain: 306 citing papers, 3.4% of this breakdownCanada: 303 citing papers, 3.4% of this breakdownAustralia: 274 citing papers, 3.1% of this breakdownNetherlands: 230 citing papers, 2.6% of this breakdownJapan: 222 citing papers, 2.5% of this breakdownSwitzerland: 157 citing papers, 1.8% of this breakdown
0%31.2%Other 21.5%

Fields

  • Medicine75.5%
  • Biochemistry, Genetics and Molecular Biology18.8%
  • Immunology and Microbiology2.8%
  • Environmental Science0.8%
  • Computer Science0.7%
  • Engineering0.6%
  • Other0.8%

Topics

  • Acute Myeloid Leukemia Research15.8%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment5.8%
  • Cancer Genomics and Diagnostics5.6%
  • Chronic Myeloid Leukemia Treatments5.2%
  • Acute Lymphoblastic Leukemia research4.3%
  • Chronic Lymphocytic Leukemia Research3.4%
  • Other59.9%

Coauthors

All papers

Open in search
  1. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Joop H. Jansen, Rashmi Kanagal‐Shamanna, Hagop M. Kantarjian, Christian P. Kratz, Xiaoqiu Li, Megan S. Lim, Keith R. Loeb, Sanam Loghavi, Andrea N. Marcogliese, Soheil Meshinchi, Phillip Michaels, Kikkeri N. Naresh, Yasodha Natkunam, Reza Nejati, German Ott, Eric Padron, Keyur P. Patel, Nikhil Patkar, Jennifer Picarsic, Uwe Platzbecker, Irene Roberts, Anna Schuh, William A. Sewell, Reiner Siebert, Prashant Tembhare, Jeffrey Tyner, Srđan Verstovšek, Wei Wang, Brent L. Wood, Wenbin Xiao, Cecilia C.S. Yeung, Andreas Hochhaus - Leukemia 2022 cited by 3,904

  2. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2020 cited by 649

  3. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Haematology 2022 cited by 239

  4. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2018 cited by 571

  5. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Niko Beerenwinkel, P. Andrew Futreal, Koichi Takahashi - Nature Communications 2020 cited by 387

  6. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Attilio Orazi, Elli Papaemmanuil, Andreas Reiter, David M. Ross, Michael R. Savona, Akiko Shimamura, Radek C. Skoda, Françesc Solé, Richard M. Stone, Ayalew Tefferi, Matthew J. Walter, David Wu, Benjamin L. Ebert, Mario Cazzola - Blood 2022 cited by 208

  7. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2024 cited by 146

  8. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 cited by 400

  9. Ibrutinib and Venetoclax for First-Line Treatment of CLL

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Varsha Gandhi, William G. Wierda - New England Journal of Medicine 2019 cited by 504

  10. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Blood Advances 2022 cited by 112

  11. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2016 cited by 386

  12. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

    Authors: , , , , , , , , , , , , , , , , - Blood Advances 2020 cited by 181

  13. Ultrasensitive NGS MRD assessment in Ph+ ALL : Prognostic impact and correlation with RT‐PCR for BCR::ABL1

    Authors: , , , , , , , , , , , , , , , , , - American Journal of Hematology 2023 cited by 73

  14. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements

    Authors: , , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2021 cited by 99

  15. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial

    Authors: , , , , , , , , , , , , , , , - The Lancet Haematology 2022 cited by 82

  16. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

    Authors: , , , , , , , , , , , , , , , , , , , - Blood 2023 cited by 61

  17. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

    Authors: , , , , , , , , , , , , - American Journal of Hematology 2015 cited by 315

  18. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2021 cited by 115

  19. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Blood Advances 2022 cited by 56

  20. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2016 cited by 297

  21. Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

    Authors: , , , , , , , , , , , , - Blood 2016 cited by 253

  22. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Blood Advances 2020 cited by 156

  23. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood Cancer Discovery 2020 cited by 97

  24. Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2022 cited by 64